Welcome to epitype GmbH in Jena

Since 2012, we have been researching cancer diagnostics on a molecular biological basis – initially as oncgnostics GmbH and since 2025 as epitype GmbH. Our cancer tests are used in cancer screening and diagnosis.

Our first product, GynTect®, was developed with the aim of improving cervical cancer screening. The molecular biological test for cervical cancer has been on the market since 2015 and is an example of the technology in which we, as a biotech company, specialize: Highly informative biomarkers, patented by us, form the heart of the company. Experienced scientists work together on innovative cancer diagnostics for the future.

Epitype GmbH – Molecular Biotechnology from Jena

Located in the heart of Jena, we, epitype GmbH, utilize the advantages of the university city to work as a young research team on innovations in the field of molecular diagnostics. Experienced scientists can thus work together to create the foundations for improved cervical cancer diagnostics in the future.

Products

The GynTect® and ScreenYu Gyn® tests provide fast and reliable support in the early detection of cervical cancer.

More information

About us

The management and highly motivated team of epitype GmbH consist of industry-experienced and ambitious scientists.

More information

Contact us

Partner oncgnostics GmbH

If you have any questions about our products and our research, we look forward to hearing from you.

More information

GynTect® could be a very good addition to tests for infections with human papillomaviruses. The data indicate that the test could identify those among the many HPV-infected women who require a precise clarification of a precancerous lesion.

Epitype has identified and clinically validated patent-protected biomarkers. These can be used for a wide variety of cancer diagnostics. This offers strategic partners from the pharmaceutical and diagnostics industries access to innovative and reliable testing methods in a growth market.

News and current events

Biotechnologieunternehmen aus Jena stellt Insolvenzantrag: oncgnostics GmbH

Jena Biotechnology Company Files for Insolvency

Jena, Thuringia, March 31, 2025. Jena-based Oncgnostics GmbH has filed for insolvency. The Gera District Court has ordered and appointed lawyer Kai Dellit from the law firm hww hermann wienberg wilhelm as the provisional insolvency administrator.…
Read more
Bachelor thesis in biotechnology companies: An experience reportoncgnostics GmbH

Bachelor thesis in biotechnology companies: From research to diagnostics 

What can emerge from basic research? This question followed Lena Bernstein during her studies in Biochemistry and Molecular Biology at the University of Jena. To find answers, she chose to write her bachelor’s thesis at a biotechnology company.…
Read more
Ärztin schaut durch ein Kolposkop. Symbolbild für die Pressemeldung der oncgnostics GmbH: Methylierungstests beim Gebärmutterhalskrebs-Screening könnten invasive Verfahren um bis zu 75 % reduzieren.Peakstock / Shutterstock

Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%

Porto / Jena, November 26, 2024 – Methylation tests could significantly increase the accuracy of cervical cancer screening and reduce referrals for colposcopy, which would, in turn, put less strain on the healthcare system. A recent study…
Read more

Individual projects in our company are co-financed by the European Union with ERDF and ESF funds and the Free State of Thuringia (Thuringian Ministry of Economics, Science and Digital Society).